Oxford BioMedica Shares Rise on Transformational Deal Talks, Revenue Growth Expectation

By Ian Walker

Shares of Oxford BioMedica rose 16% in early trade Wednesday after the company said it is in exclusive talks to buy European CDMO ABL Europe from Institut Merieux for 15 million pounds ($18.6 million) in shares, as part of a pure-play CDMO transformation.

The U.K. gene and cell therapy company added that it is on track for revenue…